Overview:

The Hepatitis B Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatments. Dosing information is provided for Intron A, lamivudine, Hepsera, and Baraclude. General information is included on sales of Hepsera.
 
 Disease and Therapy Reviews were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format.  These reports are prepared by the senior market research team of Timely Data Resources.  Each Disease and Therapy Review provides a concise analysis of the most important information about a particular disease, its treatment, and the market opportunities.  Reports begin with an overview of the condition, and also contain tables that summarize the available worldwide incidence and prevalence data for the condition, a review of current diagnosis strategies and treatment options, general information about the market size, and information about important market trends.  The data contained in these reports comes from key industry secondary data sources, such as the Timely Data Resources Incidence and Prevalence Database, and Lange's Current Medical Diagnosis and Treatment.  This information is supplemented by reviews of analyst reports, company reports, and medical websites.  Sources and references are provided.

I. OVERVIEW
General description of the condition
High-risk groups
Disease progression and symptoms
Chronic infection

II. INCIDENCE, PREVALENCE AND MORTALITY
Incidence trends
Incidence Table (US, Canada, UK, France, Germany, Italy, Spain, China, Latin America, Worldwide)
Prevalence Table (US, Canada, Mexico, UK, Italy, Spain, Japan, China, India, Worldwide)
Mortality Table (US, China, Europe, Africa, the Americas, Eastern Mediterranean, Southeast Asia, Western Pacific Worldwide)

III. DIAGNOSIS
Markers
Common serologic patterns

IV. TREATMENT
Vaccination
Treatment of acute infection
Treatment of chronic infection

V. DOSING AND TREATMENT COSTS
Vaccination
Chronic infection

VI. MARKET SIZE
Sales information for key pharmaceuticals

VII. FUTURE THERAPIES

VIII. COMMENTS

IX. REFERENCES/RESOURCES